For more in-depth information, please visit the study's ClinicalTrials.gov page.
To enroll in this trial:
Fill out the Contact Us form. Be sure to note on the form that you are interested in enrolling in the Adult Clinical Trial.
Phase II trial of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial and spinal cord ependymoma in adults.
The objective of the clinical trial is to measure the effectiveness of this regimen in patients with recurrent ependymoma, including low grade and anaplastic tumors occurring in either the brain or the spinal cord. The study will also examine the tumor tissue to determine if there are specific markers that predict the effectiveness of this treatment regimen. Estimated Enrollment: 50 patients.
Proven ependymoma or anaplastic ependymoma. Central review of pathology is required.
Age 18 years or older
Able to undergo MRI scans
Normal bone marrow, kidney and liver function
No active heart disease, active infections or problems with wound healing.
Not pregnant or breast feeding
For more detailed information and questions about this Clinical Trial please contact us.